Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Watershed Medical Inc. is currently prosecuting patents in the Biotechnology & Pharmaceuticals technology area. The portfolio contains 2 pending office actions, which are being reviewed by 2 distinct examiners. This ratio of actions to examiners suggests that each pending matter is receiving independent attention from different officials, which may lead to diverse prosecution outcomes.
The company's active cases are located in a pair of distinct art units. This indicates that the portfolio covers multiple technical specialties within the biotechnology sector. Managing prosecution across multiple art units requires familiarity with the specific examination trends and guidelines unique to each unit, as well as a flexible approach to different technical standards.
SCOTLAND, REBECCA LYNN is identified as the busiest examiner, with 1 pending office action. Although this examiner is the busiest, they only handle a single action out of the total pending actions for the company. This distribution of a single pending action per examiner means that the portfolio's success is not overly dependent on any single individual's examination style, providing a level of risk diversification.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SCOTLAND, REBECCA LYNN | 1 | 0.0% | +0.0% |
| CHANG, KYUNG SOOK | 1 | 60.4% | +40.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18858722 | FORMULATION FOR TREATING URINARY SYSTEM DISORDERS | SCOTLAND, REBECCA LYNN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18285645 | FORMULATION AND METHOD FOR TREATMENT OF URINARY SYSTEM DISORDERS | CHANG, KYUNG SOOK | 86d overdue |
| Art Unit | Apps |
|---|---|
| 1615 | 1 |
| 1613 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18858722 | FORMULATION FOR TREATING URINARY SYSTEM DISORDERS | SCOTLAND, REBECCA LYNN | 1615 | §102§103§112Other | Non-Final OA | — | Pending | Oct 21, 2024 |
| 18285645 | FORMULATION AND METHOD FOR TREATMENT OF URINARY SYSTEM DISORDERS | CHANG, KYUNG SOOK | 1613 | §103§112DP | Final Rejection | 86d overdue | Pending | Oct 04, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial